Latest Macular degeneration Stories
TORONTO, Nov. 15, 2012 /PRNewswire/ -- In response to the November 11, 2012 press release issued by the American Academy of Ophthalmology (AAO) Task Force on Genetic Testing, ArcticDx Inc. (Arctic) maintains that Macula Risk®, its laboratory developed test (LDT) for AMD, is of the highest standard and proven to add to the accuracy of clinical assessment alone in its intended use of risk stratification for AMD patients. While in general agreement with the Task Force's Recommendations...
SAN DIEGO, Nov. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of...
Report on devices' potential as visual aids to be presented at the 116th Annual Meeting of the American Academy of Ophthalmology People who have eye diseases that damage their central vision can regain the ability to read quickly and comfortably by using digital tablets, according to a recent study. The research found that people with moderate vision loss could increase their reading speed by 15 words-per-minute, on average. Using a tablet with a back-lit screen resulted in the fastest...
SARATOGA, Calif., Nov. 8, 2012 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today it has received a Health Canada Medical Device License to market the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Canada. The telescope implant is an integral component of a new patient care program called...
SARATOGA, Calif., Nov. 8, 2012 /PRNewswire/ -- VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the upcoming scientific and corporate presentations on its implantable telescope technology. The telescope implant is an integral component of a new patient care program called CentraSight®, which has been developed to...
New E-Scoop glasses improve way of life for patients suffering with macular degeneration (ARMD). Minneapolis, MN (PRWEB) October 21, 2012 New lens technology helps correct a basic problem experienced by those with macular degeneration. Recently developed new E-Scoop lenses from Holland now enable doctors to help patients with one of the chief complaints associated with macular degeneration—cloudy vision. Dr. Palmer, a low vision optometrist who sees patients in the Twin Cities area, and...
Ophthalmology Industry to See Eye-Watering DME Growth with global DME market forecast to reach $985m in 2018 whereas Global Ophthalmology Drugs and Devices Market is Expected to Reach $52.4 Billion by 2017. Dallas, Texas (PRWEB) October 21, 2012 In 2011, the global ophthalmology therapeutics market was estimated to be around $10 billion, growing at a Compound Annual Growth Rate (CAGR) of 7.2% between 2004 and 2011. The glaucoma market was the largest segment followed by Wet-AMD. These...
TARRYTOWN, N.Y., Oct. 18, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed one-year results from the VIEW 1 and VIEW 2 Phase 3 studies of EYLEA (aflibercept) Injection were published online in the journal Ophthalmology ahead of a future print publication. The publication can be accessed at http://digitalreprints.elsevier.com/t/28599. "The article published today provides additional details about the VIEW 1 and VIEW 2 studies that...
Lawrence LeBlond for redOrbit.com - Your Universe Online Age-related Macular Degeneration (AMD) is a condition that generally occurs in people over the age of 50, but also occurs in higher numbers of people who smoke, who are white, and people who have a family history of the often debilitating condition. And for those who had gone through AMD testing, they had generally had to sit in a darkened room for 20 minutes before testing had begun. But now, researchers from Australia’s Vision...
April Flowers for redOrbit.com - Your Universe Online Columbia University ophthalmologists and stem cell researchers have developed an experimental treatment for blindness using the patient's skin cells, which has improved the vision of blind mice in testing. The findings of this research, published online in the journal Molecular Medicine, suggest that induced pluripotent stem cells (iPS) could soon be used to improve vision in people with macular degeneration and other eye retina...
